Cargando…
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Biologics are vital to the management of patients with rheumatic and musculoskeletal diseases such as rheumatoid arthritis and other inflammatory and autoimmune conditions. Nevertheless, access to these highly effective treatments remains an unmet medical need for many people around the world. As pa...
Autores principales: | Mysler, Eduardo, Pineda, Carlos, Horiuchi, Takahiko, Singh, Ena, Mahgoub, Ehab, Coindreau, Javier, Jacobs, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839048/ https://www.ncbi.nlm.nih.gov/pubmed/26920148 http://dx.doi.org/10.1007/s00296-016-3444-0 |
Ejemplares similares
-
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017) -
Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani, Nizar Abdulateef, et al.
Publicado: (2018) -
Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey
por: Castañeda‐Hernández, Gilberto, et al.
Publicado: (2019) -
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020) -
Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)